Sandeep Joshi

Delhi, Uttarakhand

Founder Editor at ictflash.com

Founder and Editor at uttarakhandpanorama.com

Journalist (ex-The Hindu, PTI, Pioneer)....Now a free bird...

Featured in: Favicon

indiatimes.com Favicon

indianexpress.com Favicon

mdpi.com

thehindu.com Favicon

scroll.in

asianage.com Favicon

dailypioneer.com Favicon

inderscience.com Favicon

delveinsight.com Favicon

medium.com + 8 more

Articles

The Shifting IgG4-Related Disease Treatment Paradigm

1 week ago | delveinsight.com | Sandeep Joshi

IgG4-related disease (IgG4-RD) was first identified as a systemic condition between 2001 and 2003 in a group of Japanese patients. Subsequently, in 2011, Japan’s Ministry of Health, Labor and Welfare introduced the first diagnostic criteria for the disease.
Opportunity or Crisis for Big Players?

2 weeks ago | delveinsight.com | Sandeep Joshi

For decades, blockbuster drugs have fueled the pharmaceutical industry’s golden age. But as the 2020s unfold, a familiar threat is resurfacing with unprecedented intensity: the Loss of Exclusivity (LOE). With patents on multibillion-dollar therapies nearing expiry, pharma giants are once again bracing for revenue shocks. Yet this time, the stakes are higher—and the playbooks are different.
HT Syndication: IICT: India's Bold Leap into the Creative Future at WAVES 2025

2 weeks ago | htsyndication.com | Sandeep Joshi

India, June 10 -- The announcement by Prime Minister Narendra Modi at World Audio Visual & Entertainment Summit-WAVES 2025 in Mumbai last month to establish the Indian Institute of Creative Technology (IICT) is not just an only budgetary provision but a firm determination and bold declaration of the leadership with intent - "Na ruka hai, na rukega, ye desh hamesha aage hi badega".
IICT: India’s Bold Leap into the Creative Future at WAVES 2025

2 weeks ago | dailypioneer.com | Sandeep Joshi

The announcement by Prime Minister Narendra Modi at World Audio Visual & Entertainment Summit-WAVES 2025 in Mumbai last month to establish the Indian Institute of Creative Technology (IICT) is not just an only budgetary provision but a firm determination and bold declaration of the leadership with intent — “Na ruka hai, na rukega, ye desh hamesha aage hi badega”.
The Growing Thymidine Kinase 2 Deficiency Treatment Landscape

2 weeks ago | delveinsight.com | Sandeep Joshi

Thymidine kinase 2 deficiency (TK2d) is a rare and life-threatening genetic condition and a type of mitochondrial disease. It stems from mutations in the TK2 gene, which is essential for the replication of mitochondrial DNA (mtDNA). These mutations lead to a depletion of mtDNA, resulting in profound muscle weakness and various systemic complications. According to DelveInsight’s analysis, there were nearly 1,200 prevalent cases of TK2d across the 7MM in 2024.
5 Promising Dry Eye Disease Drugs to Watch

3 weeks ago | delveinsight.com | Sandeep Joshi

Upcoming Contenders in Dry Eye Disease Drug Space: 5 Therapies to Watch Post-TRYPTYR ApprovalShare Home Blog Upcoming dry eye disease drugsThe recent approval of the dry eye disease drug TRYPTYR has heightened competition among pharmaceutical companies. Six years after spinning off from Novartis and going public, eye care company Alcon has secured its first FDA approval for a prescription medication targeting dry eye disease.
Navigating the Dry Eye Disease Treatment Landscape

3 weeks ago | delveinsight.com | Sandeep Joshi

Dry eye disease (DED) is a common yet often underestimated condition affecting millions worldwide. Characterized by insufficient tear production or poor tear quality, it leads to persistent eye discomfort, irritation, and vision problems. Studies suggest that up to 30% of the adult population may experience some degree of dry eye symptoms, with prevalence increasing with age and certain environmental factors.
Comparison of Target Classes in Multiple Sclerosis Treatment

4 weeks ago | delveinsight.com | Sandeep Joshi

Multiple sclerosis is a chronic, immune-mediated neurodegenerative disorder characterized by inflammation, demyelination, and gradual axonal degeneration within the central nervous system (CNS). While a range of disease-modifying therapies (DMTs) have been approved, many offer limited efficacy in slowing disease progression or preventing long-term disability, particularly in progressive forms of multiple sclerosis.
The Cure Conundrum

1 month ago | delveinsight.com | Sandeep Joshi

Table of ContentsToggleLeigh syndrome, also called subacute necrotizing encephalomyelopathy, is a rare and serious genetic neurometabolic condition classified as a primary mitochondrial disease. It is associated with mutations in more than 75 genes, most of which are involved in cellular energy production. However, because many cases do not have a confirmed genetic cause, the list of implicated genes is likely incomplete.
Zynyz Clears a New Path in Anal Cancer

1 month ago | delveinsight.com | Sandeep Joshi

Following two simultaneous FDA approvals, Incyte’s PD-1 inhibitor Zynyz has made a comeback in the treatment of anal cancer, four years after being initially rejected by the agency.